Abstract:Background Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy has not been evaluated well in acute myeloid leukemia (AML), and basic information on immune checkpoint (IC) expression levels for comprehensively evaluating the prognosis of patients with AML is lacking. Methods The prognostic value of ICs in AML patients was explored by using RNA-seq and mutant data of 176 AML patients from the Cancer Genome Atlas (TCGA) database and further validated the finding using bone marrow (BM) samples from 62 patients with de novo AML from our department by quantitative real-time PCR. Results Both TCGA data and validation results indicated that high expression of PD-1, PD-L1, and PD-L2 was associated with poor overall survival (OS) in AML patients. In addition, increased co-expression of PD-1 and CTLA-4 (3-year OS: 30% vs 0% (TGCA data), 57% vs 31% (validation group), respectively) or PD-L2 and CTLA-4 (3-year OS: 20% vs 0% (TGCA data), 57% vs 33% (validation group), respectively) correlated with poor AML OS (P < 0.05). Moreover, co-expression of PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 correlated with poor OS in AML patients with FLT3mut, RUNX1mut, and TET2mut, respectively (P < 0.05). Conclusions High expression of ICs in the BM leukemia cells of AML patients correlated with poor OS. Co-expressions of PD-1/CTLA-4, PD-L2/CTLA-4, PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 might be used as novel immune predictors for patient OS in AML, and might guide the best choice for precision immune checkpoint blockade in the future. Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy has not been evaluated well in acute myeloid leukemia (AML), and basic information on immune checkpoint (IC) expression levels for comprehensively evaluating the prognosis of patients with AML is lacking. The prognostic value of ICs in AML patients was explored by using RNA-seq and mutant data of 176 AML patients from the Cancer Genome Atlas (TCGA) database and further validated the finding using bone marrow (BM) samples from 62 patients with de novo AML from our department by quantitative real-time PCR. Both TCGA data and validation results indicated that high expression of PD-1, PD-L1, and PD-L2 was associated with poor overall survival (OS) in AML patients. In addition, increased co-expression of PD-1 and CTLA-4 (3-year OS: 30% vs 0% (TGCA data), 57% vs 31% (validation group), respectively) or PD-L2 and CTLA-4 (3-year OS: 20% vs 0% (TGCA data), 57% vs 33% (validation group), respectively) correlated with poor AML OS (P < 0.05). Moreover, co-expression of PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 correlated with poor OS in AML patients with FLT3mut, RUNX1mut, and TET2mut, respectively (P < 0.05). High expression of ICs in the BM leukemia cells of AML patients correlated with poor OS. Co-expressions of PD-1/CTLA-4, PD-L2/CTLA-4, PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 might be used as novel immune predictors for patient OS in AML, and might guide the best choice for precision immune checkpoint blockade in the future.

PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia

Increased PD-1+Tim-3+ Exhausted T Cells in Bone Marrow May Influence the Clinical Outcome of Patients with AML.

Higher TIGIT+ γδ TCM cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML

A Skewed Distribution and Increased PD-1+Vβ+CD4+/CD8+ T Cells in Patients with Acute Myeloid Leukemia

3103 – OPTIMAL COMBINATION OF IMMUNE CHECKPOINTS PREDICTS ADVERSE OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Higher TIGIT+CD226- Γδ T Cells in Patients with Acute Myeloid Leukemia

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

Expression Patterns of Immune Checkpoints in Acute Myeloid Leukemia

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review

Lactate acid promotes PD-1 + Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia

INCREASED TIGIT+CD226-Gamma Delta T CELLS ARE ASSOCIATED WITH DIFFERENT CLINICAL STATUS IN AML

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+æ T Cells in AML Patients

PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway

PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

Higher frequency of peripheral blood CD103+CD8+ T cells with lower levels of PD-1 and TIGIT expression related to favorable outcomes in leukemia patients

Murine Regulatory CD4+ T Cells Are Increased in Leukemic Spleens and Show High Co-Expression of Co-Regulatory Molecules CD39, CD73, PD1, and TIGIT